|
Volumn 12, Issue 5, 2001, Pages 633-641
|
The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: A feasibility study
a b a c d e a |
Author keywords
Docetaxel; Estramustine; Hormone refractory prostate cancer; Quality of life
|
Indexed keywords
DOCETAXEL;
ESTRAMUSTINE;
HORMONE;
HYDROCORTISONE;
NARCOTIC ANALGESIC AGENT;
ADULT;
AGED;
ANXIETY;
ARTICLE;
CANCER PAIN;
CAREGIVER;
CLINICAL ARTICLE;
CLINICAL TRIAL;
COMORBIDITY;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG USE;
EMOTION;
FEASIBILITY STUDY;
HEALTH STATUS;
HUMAN;
MALE;
MEASUREMENT;
MICTURITION;
MULTICENTER STUDY;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROSTATE CANCER;
QUALITY OF LIFE;
SIDE EFFECT;
SPOUSE;
TREATMENT OUTCOME;
WELLBEING;
ADMINISTRATION, ORAL;
AGED;
AGED, 80 AND OVER;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
ANXIETY;
DRUG RESISTANCE, NEOPLASM;
EMOTIONS;
ESTRAMUSTINE;
FEASIBILITY STUDIES;
FEMALE;
HEALTH STATUS;
HUMANS;
HYDROCORTISONE;
INFUSIONS, INTRAVENOUS;
MALE;
MENTAL HEALTH;
MIDDLE AGED;
PACLITAXEL;
PAIN;
PROSTATIC NEOPLASMS;
QUALITY OF LIFE;
SEXUAL BEHAVIOR;
SPOUSES;
TAXOIDS;
|
EID: 0034986608
PISSN: 09237534
EISSN: None
Source Type: Journal
DOI: 10.1023/A:1011102619058 Document Type: Article |
Times cited : (46)
|
References (38)
|